Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced that preclinical and Phase 1 clinical data describing XPO1 inhibition with selinexor (KPT-330), the Company’s lead, oral Selective Inhibitor of Nuclear Export / SINE™ compound, in ovarian cancer models and in patients, were published online in Clinical Cancer Research. The paper, entitled “Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum Resistant Ovarian Cancer,” discusses scientific results supporting selinexor’s potential as a new therapeutic strategy for platinum resistant ovarian cancer.
Published data have shown that XPO1 mRNA overexpression is correlated with decreased survival and platinum resistance in human ovarian cancer. Inhibition of XPO1 with Karyopharm’s SINE compounds decreased cell viability and synergistically restored platinum sensitivity in preclinical models. In addition, selinexor treatment, alone and in combination with cisplatin, markedly decreased tumor growth and prolonged survival in a platinum-resistant ovarian cancer in vivo model. These results were further confirmed in a Phase 1 clinical trial, which evaluated single agent oral selinexor in patients with late-stage, recurrent, and heavily pre-treated, platinum resistant ovarian cancer. In this study, selinexor had manageable toxicity and tumor growth was halted in three of five evaluable patients, including one patient with a confirmed partial response. These results lead to the Phase 2 clinical study “SIGN” (Selinexor in Gynecologic Malignancies), with results to be released in an oral presentation at the European Society of Medical Oncology (ESMO) 2016 annual meeting in Copenhagen.
“Ovarian cancer mortality rates are high, with chemoresistance representing the major cause of treatment failure. These data are encouraging, not only because they demonstrate that inhibition of XPO1 with selinexor significantly increased tumor killing regardless of platinum sensitivity, but also because selinexor can be given safely in this late-stage, heavily pretreated and platinum-resistant disease setting,” said John A. Martignetti, MD, PhD, Associate Professor, The Mount Sinai Hospital, and co-lead author of the paper.
Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm commented, “These findings are important because they provide insights into the potential value of XPO1 as a therapeutic target in ovarian cancer. We look forward to expanding on our growing body of selinexor clinical data in early October when we report results from the Phase 2 SIGN study in patients with gynecological malignancies, including ovarian cancer, at the ESMO Meeting.” (Original Source)
Shares of Karyopharm are currently trading at $9.76, up $0.07 or 0.72%. KPTI has a 1-year high of $19.41 and a 1-year low of $4.83. The stock’s 50-day moving average is $8.45 and its 200-day moving average is $8.31.
On the ratings front, KPTI stock has been the subject of a number of recent research reports. In a report issued on September 8, H.C. Wainwright analyst Shaunak Deepak reiterated a Buy rating on KPTI, with a price target of $16, which implies an upside of 65% from current levels. Separately, on September 6, Baird’s Michael Ulz reiterated a Buy rating on the stock and has a price target of $16.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Shaunak Deepak and Michael Ulz have a total average return of -18.0% and -2.1% respectively. Deepak has a success rate of 41% and is ranked #3929 out of 4185 analysts, while Ulz has a success rate of 58% and is ranked #3012.
Overall, 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $15.00 which is 54.8% above where the stock closed yesterday.
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its selective inhibitors of nuclear export compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell.